a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain
Industry Biotechnology
A.I.dvisor indicates that over the last year, ANNX has been loosely correlated with MGTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ANNX jumps, then MGTX could also see price increases.
Ticker / NAME | Correlation To ANNX | 1D Price Change % | ||
---|---|---|---|---|
ANNX | 100% | -3.36% | ||
MGTX - ANNX | 43% Loosely correlated | -5.68% | ||
DNTH - ANNX | 40% Loosely correlated | -3.26% | ||
FDMT - ANNX | 40% Loosely correlated | +4.02% | ||
ERAS - ANNX | 39% Loosely correlated | -1.40% | ||
KYMR - ANNX | 38% Loosely correlated | -5.52% | ||
More |
Ticker / NAME | Correlation To ANNX | 1D Price Change % |
---|---|---|
ANNX | 100% | -3.36% |
novel therapies theme (2 stocks) | 66% Closely correlated | -5.02% |
biopharmaceutical theme (10 stocks) | 46% Loosely correlated | -2.71% |
brain theme (2 stocks) | 42% Loosely correlated | -2.92% |
drugs theme (254 stocks) | 40% Loosely correlated | -1.67% |
eye theme (8 stocks) | 35% Loosely correlated | -2.79% |